Funding momentum GLNT recently secured a 2.1M Phase II SBIR grant from NIH/NINDS to advance DBS optimization using Kinesia technology, signaling strong R&D funding and potential for expanded clinical studies and government-funded projects.

Movement disorder focus Core markets include movement disorders such as Parkinson’s disease with Kinesia and DBS optimization, presenting opportunities to cross-sell monitoring, remote diagnostics, and integration with telemedicine to clinics, hospitals, and research centers treating PD.

Strategic partnerships Recent collaboration with Henry Schein Medical UK suggests appetite for distribution partnerships and channel expansion in медицин supply networks, offering avenues to widen geographic reach and accelerate sales in new regions.

Wearable integration Past launches of Apple Watch and iPhone compatible KinesiaU systems demonstrate receptivity to consumer-grade device integration, creating upsell potential for wearables-enabled remote monitoring packages for education, research, and home health monitoring.

SMB to mid-market growth Company size and revenue positioning (11-50 employees; $1M–$10M revenue) align with targeting small to midsize clinics, universities, and regional hospitals that need high-quality, configurable bioinstrumentation with scalable remote capabilities, supported by existing WOOCOMMERCE and WordPress presence.